Predictors of disease-free survival
| HR | 95% CI | P value | |
| Body mass index (kg/m2) | |||
| Normal | 1 | – | |
| Overweight (≥25 kg/m2) | 3 | 1.2 to 7.7 | 0.02 |
| MRI size >3 cm | |||
| No | 1 | – | |
| Yes | 3.05 | 1.23 to 7.51 | 0.016 |
| Clinical size >3 cm | |||
| No | 1 | – | |
| Yes | 2.65 | 0.99 to 7.08 | 0.052 |
| Biggest size* >3 cm | |||
| No | 1 | – | |
| Yes | 2.12 | 0.85 to 5.30 | 0.26 |
| Smoking | |||
| No | 1 | – | |
| Yes | 0.54 | 0.1 to 2.3 | 0.41 |
| Previous conization | |||
| No | 1 | – | |
| Yes | 0.38 | 0.09 to 1.64 | 0.19 |
| Histological type | |||
| SCC | 1 | – | |
| Other | 0.8 | 0.3 to 2.5 | 0.71 |
| FIGO stage | |||
| Stage I | 1 | – | |
| Stage II | 2.5 | 0.7 to 8.8 | 0.16 |
| Tumor differentiation | |||
| Poorly differentiated | 1 | – | |
| Moderately differentiated | 0.9 | 0.2 to 3.8 | 0.97 |
| Well differentiated | 0.9 | 0.3 to 2.7 | 0.97 |
| LVSI | |||
| No | 1 | – | |
| Yes | 1.7 | 0.4 to 8.1 | 0.48 |
| Dosimetric examination | |||
| No | 1 | – | |
| Yes | 0.9 | 0.2 to 3.6 | 0.63 |
| Final node status | |||
| Negative | 1 | – | |
| Micrometastasis | 1.1 | 0.3 to 4.8 | 0.9 |
| PCR | |||
| No | 1 | – | |
| Yes | 0.6 | 0.2 to 1.6 | 0.34 |
| Delay between BT and HT | |||
| <63 days | 1 | – | |
| >63 days | 1.3 | 0.5 to 3.5 | 0.6 |
*Biggest size was defined as either the clinical or MRI size, plus any infiltrative carcinoma found in the previous conization if applicable.
BMI, body mass index; BT, brachytherapy; FIGO, International Federation of Gynecology and Obstetrics;HR, hazard ratio; HT, hysterectomy; LVSI, lymphovascular space involvement;MRI, magnetic resonance imaging; PCR, pathological complete response based on the surgical specimen; SCC, squamous cell carcinoma.